Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. - Wikidata - awgldk - TriplyDB

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

http://www.wikidata.org/entity/Q42705363

about

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.Understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin Host genomics and HCV treatment response.Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management.The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interfer IL28B Polymorphisms Among Latin American HCV Patients

P2860

Q30365599-23C48F3E-12C5-4BD1-BB57-E5EA8789ADDF Q34126254-E922CE9C-581B-4CCD-A317-2E92BB85FA7E Q35610571-D131CC11-3293-4969-A3CD-C8612C0FC97C Q35992420-C91A3376-BD23-4FB8-B194-F8696B9FC696 Q36224697-E8B29678-32EC-4FFD-B96E-644BD0F6B7C3 Q36667084-BC7C092F-1025-4623-89FA-EA9B76260764 Q36888177-2B861ADB-9303-46FF-BF35-85417D451401 Q36967094-733125D6-B3E8-46B9-9C7E-F47FBDC86D9C Q37932036-1C53176D-532F-4362-B29E-927A08C4008E Q38180719-D21EE312-3DDE-4519-8259-473D6D420343 Q42981009-6B58187D-D692-4363-ADD7-9F6109659F7B Q42986101-71FCAA76-23A8-4F54-87CF-EE00057839B7 Q58379795-E3402903-9909-4D72-83D4-36C4729F8147

P2860

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients.

http://www.wikidata.org/entity/Q42705363

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@en

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@nl

type

label

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@en

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@nl

prefLabel

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@en

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@nl

P1433

Q42705363-6E3C475B-AF8F-4A1B-9FA9-FDF6C5FA6696

P1476

Q42705363-906F183F-54A6-44BC-B330-9C8C2E22D4B5

P2093

Q42705363-003C032F-FC9B-4FBF-8A4D-675988D5C1F3

Q42705363-2AC61003-E6F8-4C49-9C67-E48E357CDAE8

Q42705363-7CE3D9E0-A533-429B-956A-B450C201BD46

Q42705363-A6378714-C503-4195-89F4-798AF9AC0347

Q42705363-AB559CC7-9DCB-4196-A6D1-1798DA121341

Q42705363-AD154F5E-4FE7-46AE-8C65-E23FC10D11B6

Q42705363-E0AEA717-C671-4422-A41E-592646250C65

P2860

Q42705363-094E308C-09A8-44AB-8784-4CF922753C21

Q42705363-0E8D7F17-3251-4AED-BF75-ADF5A1D7FC54

Q42705363-137AE59A-B3D8-4C9E-BB4D-B63E036BB478

Q42705363-13BCE85A-B142-4142-BD76-7BF1F9FA41E0

Q42705363-21D3245A-60B6-49D8-A749-67AD21EAFC7B

Q42705363-2BCD6FCA-9DBB-4EF9-A69D-76155120CC41

Q42705363-3900C555-A132-4856-899C-A2E5858BAB0E

Q42705363-3B3AF8E9-3693-41E9-8ACE-E99EDCCFCD2E

Q42705363-63024F0B-BB55-448B-A7D1-9F3CDF704F74

Q42705363-75BC3349-FE49-4B00-8B48-1ED694452901

P304

Q42705363-62C2ED15-5A47-4C50-BAFC-5BDEF1F636EE

P31

Q42705363-8BF2C016-1590-418A-8D53-719A6B858F95

P356

Q42705363-7A397BCD-69A3-41EE-B438-4F025D721B9E

P407

Q42705363-A354FA60-BFB2-4B53-92C5-E5FEEE8C4B31

P433

Q42705363-41D51CCB-28B1-490F-AC58-2F7C069ECA0C

P478

Q42705363-C84FAA42-7BA4-49CE-B47A-6841A29F7B5F

P577

Q42705363-9CADB6DB-F3D2-4AD9-92E8-A4D580B99CBB

P5875

Q42705363-834A7A7D-C3BD-4AF2-B418-836474A411E7

P698

Q42705363-A10751C3-180B-4C32-AE9C-000025A7A3DC

P932

Q42705363-FF01C725-759E-4525-8BFC-8F1521B9ABC8

P356

QAI.0B013E3182020596

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Pharmacodynamics of PEG-IFN-[a ...... n HIV/HCV-coinfected patients.

@en

P2093

Antonio Alci Barone

http://www.w3.org/2001/XMLSchema#string

Avidan U Neumann

http://www.w3.org/2001/XMLSchema#string

Carlos Eduardo Melo

http://www.w3.org/2001/XMLSchema#string

Evaldo Stanislau Affonso de Araujo

http://www.w3.org/2001/XMLSchema#string

Harel Dahari

http://www.w3.org/2001/XMLSchema#string

Scott J Cotler

http://www.w3.org/2001/XMLSchema#string

Thomas J Layden

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

P304

95-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAI.0B013E3182020596

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49682716

http://www.w3.org/2001/XMLSchema#string

P698

21157362

http://www.w3.org/2001/XMLSchema#string

P932

3066089

http://www.w3.org/2001/XMLSchema#string